Monday morning Global Blood Therapeutics (GBT) announced the FDA has agreed to GBT’s plan to file for accelerated approval of voxelotor, a unique …

Catalyst Pharmaceutical (CPRX) stock fell about 8% between Thursday and Friday. Even though the company just announced its first FDA approval for Firdapse, …

Vertex (VRTX) is Cowen analyst’s top large-cap pick for the second year in a row. That’s how Phil Nadeau put it while increasing …

The Amarin (AMRN) saga is not over yet. Following a somewhat dramatic couple of weeks after the release of the biopharmaceutical’s drug, Vascepa, analysts …

After a series of talks with depression key opinion leaders (KOL) about Acadia Pharmaceutical’s (ACAD) Ph2 CLARITY trial, all four experts believe the …

H.C.

Stemline Therapeutics (STML) announced the European Medicines Agency (EMA) is granting accelerated assessment for the company’s marketing authorization for oral treatment, Elzonris. The …

Biopharmaceutical Vertex’ (VRTX) is working on a trial called Phase III VX-659 and Cowen analyst Phil Nadeau calls some recently released data “Good …

Paratek Pharmaceuticals (PRTK) is preparing to launch its drug NUZYRA, following FDA approval granted on October 2nd. The medication treats both community-acquired bacterial …

Nektar Therapeutics (NKTR) presented some updated results on Friday, November 9th from the melanoma expansion cohort of Phase II from PIVOT-02 study. The cancer-focused …